Examining the link between residual tumor and outcomes after targeted therapy in lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between residual viable tumor (RVT) and survival outcomes in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have undergone neoadjuvant targeted therapy. By analyzing data from patients treated at Guangdong Provincial People's Hospital, the study aims to clarify the prognostic significance of RVT in predicting disease-free and event-free survival. The findings could enhance understanding of RVT as a biomarker, potentially guiding postoperative management and risk stratification for patients. This retrospective analysis focuses on the importance of pathological evaluation of RVT to improve treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-80 years old;
* Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
* Treated with neoadjuvant targeted therapy;
* Undergoing definitive surgery.

Exclusion Criteria:

* A history of prior chemotherapy, immunotherapy, or radiotherapy.
* A history of malignancy or lung surgery;
* Missing key data.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Guibin Qiao — Guangdong Provincial People's Hospital
• Study coordinator: Guibin Qiao
• Email: guibinqiao@126.com
• Phone: +86-13602749153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Understanding what patients want from NSCLC treatment monitoring

  Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.

  Recruiting European Institute of Oncology · Milan, mI · NCT07909343

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC

  This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07841249

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• NUT Project: Nutritional Support in Thoracic Cancer

  We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.

  Recruiting Casa di Cura Dott. Pederzoli · Peschiera del Garda, Verona · NCT07817329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.